Difference between revisions of "Section 1: Introduction (from DOI: 10.1016/j.clim.2020.108427) (Q11187)"
Jump to navigation
Jump to search
(Created claim: named entity (P78): lopinavir-ritonavir drug combination (chemical - MeSH supplementary concept) (Q10863), #quickstatements; #temporary_batch_1593364886867) |
(Created claim: named entity (P78): Respiratory syncytial virus (species) (Q10866), #quickstatements; #temporary_batch_1593364886867) |
||
| Property / named entity | |||
| + | |||
| Property / named entity: Respiratory syncytial virus (species) / rank | |||
| + | Normal rank | ||
Revision as of 17:21, 28 June 2020
Publication: "COVID-19 pathophysiology: A review" published in Clin. Immunol.; 2020 Apr 20 108427; DOI: 10.1016/j.clim.2020.108427
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Section 1: Introduction (from DOI: 10.1016/j.clim.2020.108427)
|
Publication: "COVID-19 pathophysiology: A review" published in Clin. Immunol.; 2020 Apr 20 108427; DOI: 10.1016/j.clim.2020.108427
|
Statements
0 references
